Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 15/20 | 0.70 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | HRH1 | P35367 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086996 | 1.00 | CHRM2 (0.70) | CHRM2CHRM3KCNH2CHRM1CYP2D6 | |
| SCHEMBL1086995 | 1.00 | CHRM2 (0.70) | CHRM2CHRM3KCNH2CHRM1CYP2D6 | |
| SCHEMBL1087251 | 0.94 | CHRM2 (0.68) | CHRM2CHRM3KCNH2CHRM1CYP2D6 | |
| SCHEMBL1087244 | 0.94 | CHRM2 (0.68) | CHRM2CHRM3KCNH2CHRM1CYP2D6 | |
| SCHEMBL1087248 | 0.94 | CHRM2 (0.68) | CHRM2CHRM3KCNH2CHRM1CYP2D6 | |
| SCHEMBL1087246 | 0.90 | CHRM3 (0.67) | CHRM2CHRM3KCNH2CHRM1CYP2D6 | |
| SCHEMBL1087249 | 0.90 | CHRM3 (0.67) | CHRM2CHRM3KCNH2CHRM1CYP2D6 | |
| SCHEMBL1087243 | 0.90 | CHRM3 (0.67) | CHRM2CHRM3KCNH2CHRM1CYP2D6 | |
| SCHEMBL1087850 | 0.89 | CHRM2 (0.69) | CHRM2CHRM3KCNH2CHRM1CYP2D6 | |
| SCHEMBL1087852 | 0.89 | CHRM2 (0.69) | CHRM2CHRM3KCNH2CHRM1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227590-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | claimed |
| EP-1831208-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | Novartis AG (CH) | 2007-09-12 | — | — | EP | claimed |
| WO-2006066929-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | claimed |
| US-8153669-B2 | Quaternary ammonium salts as M3 antagonists | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20090227590-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| EP-1831208-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | Novartis AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066929-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227590-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM3 3/4885KCNH2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.